Study of Durvalumab plus Tremelimumab as First-line Treatment in Chinese Patients with Unresectable Hepatocellular Carinoma - TREMENDOUS

Study identifier:D419CR00026

ClinicalTrials.gov identifier:NCT05557838

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma

Medical condition

Hepatocellular Carcinoma

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Tremelimumab

Sex

All

Estimated Enrollment

210

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 22 Feb 2023
Estimated Primary Completion Date: 31 Mar 2025
Estimated Study Completion Date: 31 Mar 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria